BR0108923A - Elemento de ligação especìfico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação especìfico ou domìnio vh ou vl de anticorpo, e, para obter um elemento de ligação especìfico que liga eotaxina - Google Patents

Elemento de ligação especìfico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação especìfico ou domìnio vh ou vl de anticorpo, e, para obter um elemento de ligação especìfico que liga eotaxina

Info

Publication number
BR0108923A
BR0108923A BR0108923-4A BR0108923A BR0108923A BR 0108923 A BR0108923 A BR 0108923A BR 0108923 A BR0108923 A BR 0108923A BR 0108923 A BR0108923 A BR 0108923A
Authority
BR
Brazil
Prior art keywords
specific binding
binding element
eotaxin
antibody
methods
Prior art date
Application number
BR0108923-4A
Other languages
English (en)
Other versions
BRPI0108923B8 (pt
BRPI0108923B1 (pt
Inventor
Tristan John Vaughan
Alison Jane Wilton
Stephen Smith
Original Assignee
Cambridge Antibody Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Antibody Tech filed Critical Cambridge Antibody Tech
Publication of BR0108923A publication Critical patent/BR0108923A/pt
Publication of BRPI0108923B1 publication Critical patent/BRPI0108923B1/pt
Publication of BRPI0108923B8 publication Critical patent/BRPI0108923B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"ELEMENTO DE LIGAçãO ESPECìFICO, áCIDO NUCLEICO ISOLADO, CéLULA HOSPEDEIRA, MéTODOS PARA PRODUZIR UM ELEMENTO DE LIGAçãO ESPECìFICO OU DOMìNIO VH OU VL DE ANTICORPO, E, PARA OBTER UM ELEMENTO DE LIGAçãO ESPECìFICO QUE LIGA EOTAXINA". Elementos de ligação específicos dirigidos para eotaxina-1, particularmente anticorpos humanos e fragmentos de anticorpos contra eotaxina -1 humana e especialmente os que neutralizam atividade de eotaxina-1. Os domínios VH e/ou VL de anticorpos de fg scFv, aqui chamado CAT- 212 e os de anticorpo IgG4, aqui chamados CAT 213. Uma ou mais regiões de determinação complementares (CDRS) de domínios VH e/ou VL de CAT212/213, especialmente VH CRD3, em outras regiões de armação de anticorpos. Composições contendo elementos de ligação específicos e seu uso em métodos para inibir ou neutralizar eotaxina, incluindo métodos de tratamento do corpo humano ou animal por terapia.
BR0108923A 2000-03-03 2001-03-02 elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina BRPI0108923B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18724600P 2000-03-03 2000-03-03
PCT/GB2001/000927 WO2001066754A1 (en) 2000-03-03 2001-03-02 Human antibodies against eotaxin and their use

Publications (3)

Publication Number Publication Date
BR0108923A true BR0108923A (pt) 2003-04-22
BRPI0108923B1 BRPI0108923B1 (pt) 2018-11-13
BRPI0108923B8 BRPI0108923B8 (pt) 2021-05-25

Family

ID=22688187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108923A BRPI0108923B8 (pt) 2000-03-03 2001-03-02 elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina

Country Status (14)

Country Link
US (6) US7323311B2 (pt)
EP (1) EP1259615B1 (pt)
JP (1) JP5198704B2 (pt)
AT (1) ATE414151T1 (pt)
AU (1) AU778392B2 (pt)
BR (1) BRPI0108923B8 (pt)
CA (1) CA2401342C (pt)
DE (1) DE60136527D1 (pt)
GB (1) GB2361704C (pt)
IL (2) IL151499A0 (pt)
MX (1) MXPA02008472A (pt)
NO (1) NO20024179L (pt)
NZ (1) NZ521182A (pt)
WO (1) WO2001066754A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1259615B1 (en) 2000-03-03 2008-11-12 Cambridge Antibody Technology Limited Antibodies against eotaxin and their use
ES2736165T3 (es) 2001-08-23 2019-12-26 Rsr Ltd Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas
CN101052415A (zh) * 2003-03-24 2007-10-10 莫西亚药物公司 用于治疗和预防炎性疾病的方法和组合物
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
PL1942939T5 (pl) 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
ES2395839T3 (es) 2006-03-27 2013-02-15 Medimmune Limited Miembro de unión para el receptor GM-CSF
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
US8176867B2 (en) 2009-05-28 2012-05-15 Richard J. A. Gayton Watercraft immobilizing system
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
CN108064236B (zh) 2015-03-31 2021-12-10 免疫医疗有限公司 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法
RU2021129189A (ru) 2016-01-22 2021-11-15 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
CN109475616B (zh) 2016-06-02 2022-10-18 麦迪穆有限责任公司 针对α-突触核蛋白的抗体及其用途
WO2017212488A1 (en) * 2016-06-06 2017-12-14 Hadasit Medical Research Service And Development Ltd. Anti-eotaxin for immunoprotection and hepatoprotection
MY201852A (en) 2016-06-14 2024-03-20 Merck Sharp & Dohme Llc Anti-coagulation factor xi antibodies
TW202519263A (zh) * 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
FI940144A7 (fi) * 1991-07-15 1994-01-12 The Wellcome Foundation Ltd Vasta-aineiden tuotanto
IL103758A (en) 1991-12-13 1998-07-15 Akzo Nv Tumor specific monoclonal antibodies
JPH09507211A (ja) 1993-09-14 1997-07-22 ナショナル ハート アンド ラング インスティチュート エオタキシン：好酸球走化性サイトカイン
US6403782B1 (en) 1995-06-22 2002-06-11 President And Fellows Of Harvard College Nucleic acid encoding eotaxin
US7265201B1 (en) * 1995-06-23 2007-09-04 Millennium Pharmaceuticals, Inc. Human chemotactic cytokine
AU7097696A (en) 1995-10-05 1997-04-28 Shionogi & Co., Ltd. Novel human cc chemokine
WO1999010534A1 (en) 1997-08-22 1999-03-04 Center For Blood Research, Inc. Diagnosis and treatment of diseases with eotaxin and antagonists and agonists thereof
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CN102766210B (zh) * 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
EP1259615B1 (en) 2000-03-03 2008-11-12 Cambridge Antibody Technology Limited Antibodies against eotaxin and their use
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
GB0016138D0 (en) 2000-06-30 2000-08-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AU778392B2 (en) 2004-12-02
US20080182319A1 (en) 2008-07-31
US20120270265A1 (en) 2012-10-25
US20040014132A1 (en) 2004-01-22
CA2401342A1 (en) 2001-09-13
US8067564B2 (en) 2011-11-29
JP5198704B2 (ja) 2013-05-15
US20160257741A1 (en) 2016-09-08
IL151499A (en) 2010-06-30
ATE414151T1 (de) 2008-11-15
GB0105237D0 (en) 2001-04-18
GB2361704C (en) 2006-08-02
WO2001066754A1 (en) 2001-09-13
US9284589B2 (en) 2016-03-15
US20210277103A1 (en) 2021-09-09
AU3585201A (en) 2001-09-17
CA2401342C (en) 2010-08-03
BRPI0108923B8 (pt) 2021-05-25
BRPI0108923B1 (pt) 2018-11-13
DE60136527D1 (de) 2008-12-24
NO20024179D0 (no) 2002-09-02
US7323311B2 (en) 2008-01-29
EP1259615B1 (en) 2008-11-12
GB2361704B (en) 2002-04-10
GB2361704A (en) 2001-10-31
NO20024179L (no) 2002-11-01
MXPA02008472A (es) 2004-03-26
IL151499A0 (en) 2003-04-10
US20140294857A1 (en) 2014-10-02
EP1259615A1 (en) 2002-11-27
US10577413B2 (en) 2020-03-03
NZ521182A (en) 2004-11-26
JP2003528598A (ja) 2003-09-30
US8715961B2 (en) 2014-05-06

Similar Documents

Publication Publication Date Title
BRPI0108923B8 (pt) elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
BRPI0519775A2 (pt) proteÍna isolada de ligaÇço a antÍgeno, polinucleotÍdeo isolado, plasmÍdio e cÉlula isolada e composiÇço farmacÊutica
BRPI0417429A (pt) anticorpo monoclonal isolado ou uma porção de ligação de antìgeno deste, composição, imunoconjugado, molécula biespecìfica, vetor de expressão, célula hospedeira, camundongo transgênico, hibridoma, e, métodos de inibir uma resposta inflamatória ou autoimune, de tratar uma doença inflamatória ou autoimune, de tratar uma infecção viral ou bacteriana e de preparar um anticorpo anti-ip-10
BRPI0611414B8 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos
HRP20161338T1 (hr) Limfocitni antigen
BRPI0407833A (pt) anticorpo monoclonal humano isolado, e, método de tratar ou prevenir um distúrbio
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
DK1425389T3 (da) Interleukin-15-(IL-15)-specifikke humane antistoffer
DE60130538D1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
BRPI0214137B8 (pt) anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo
WO2004043989A3 (en) Human monoclonal antibodies to heparanase
DE60031279D1 (de) Humane monoklonale antikörper gegen prostata spezifisches membranantigen
PT2305715T (pt) Anticorpo monoclonal para a proteína de ligação a osteoprotegerina
BRPI0210405B8 (pt) anticorpo monoclonal humano, molécula biespecífica, método in vitro para inibir o crescimento de uma célula expressando egfr, para induzir a citólise de uma célula expressando egfr, e para detectar a presença de antígeno egfr ou uma célula expressando egfr em uma amostra, e, vetor de expressão
WO2004035607A3 (en) Human monoclonal antibodies against cd20
BRPI0611984A2 (pt) uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
BR0316282A (pt) Anticorpo humano isolado, hibridoma, transfectoma, célula hospedeira eucariótica ou procariótica, animal não humano ou planta transgênica, método para produzir um anticorpo monoclonal humano, composição, imunoconjugado, molécula biespecìfica ou multiespecìfica, método para inibir o desenvolvimento e/ou a proliferação de uma célula que expressa cd25, método para eliminar uma célula que expressa cd25, método para tratar ou evitar um distúrbio que envolve as células que expressam cd25, método e conjunto de diagnóstico para detectar a presença de antìgeno cd25 ou uma célula que expressa cd25, vetor de expressão, anticorpo anti-idiotìpico, e, uso do mesmo
EA200701443A1 (ru) Синтетические домены иммуноглобулина, обладающие свойствами связывания и сконструированные в участках молекулы, отличных от гипервариабельных участков
HRP20060033A2 (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
DE60328195D1 (de) Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
UA105009C2 (uk) Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
BR0112086A (pt) Anticorpos para mcp-1 humano
WO2002059154A3 (en) Neutralizing human monoclonal antibodies against hiv-1, their production and uses
SG148190A1 (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
LeBlanc Putting the CAR-T Before the Horse: How Much Disclosure is Required Under Section 112 (a) for Biotechnological Inventions?

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 15/13 , C12N 15/62 , C12N 5/10 , C07K 16/24

Ipc: C07K 16/24 (2006.01), C12N 15/19 (2006.01), C12N 1

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: MEDIMMUNE LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: MEDIMMUNE LIMITED (GB)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/03/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 02/03/2021